

- VisiPlate leverages an ultra-thin, flexible nanomaterial. What were the biggest technical and regulatory hurdles in getting such a novel material approved for first-in-human trials—and how did you validate safety and stability compared to traditional materials?
- As co-founders who met at M&TSI and later reunited, what was the most important value or skill you each brought from M&TSI that made your co-founding dynamic work? And how did you divide decision-making when clinical stakes and startup pressure were high?
- How did winning the Y-Prize help you build early momentum for Avisi? And when did you realize that VisiPlate could be more than a student idea and become a real medical product?
- As someone who pivoted from engineering to medicine, Brandon, how did your background as a CTO shape your understanding of clinical needs in ophthalmology—and are there insights you gained in medical school that would've changed how you designed VisiPlate?
- There are lots of student-founded projects that never leave the lab. What advice would you give to young innovators working at the intersection of engineering and healthcare who want to actually bring a medical device to market?